MA
Michael Ackermann, PhD, MBA
Co-Founder, Board Member and CBO, Arrivo Bioventures (Scientific Advisory Board)
Circular GenomicsTherapeutic Areas
Circular Genomics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MindLight™ | Major Depressive Disorder (MDD) - Prediction of SSRI (antidepressant) response | Commercial |
| circRNA Blood Test | Alzheimer's Disease (AD) - Diagnosis and risk prediction | Development |
| circRNA Assays | Other Neurological & Psychiatric Conditions (e.g., Parkinson's, Multiple Sclerosis, Bipolar Disorder) | Research |
Leadership Team at Circular Genomics
PS
Paul Sargeant, PhD
President and Chief Executive Officer, Member of Board of Directors
NM
Nikolaos Mellios, MD, PhD
Chief Scientific Officer, Member of Board of Directors, Cofounder
SS
Sami Shihabi
Chief Commercial Officer
DB
Dave Blivin
Managing Director, Cottonwood Technology Fund (Board of Directors)
RR
Ron Rocca
President & Chief Executive Officer, Mindera Health (Board of Directors)
JC
Joe Cook, III
Managing Director, Mountain Group Partners (Board of Directors)
WT
Waneta Tuttle, PhD
Managing Director, Tramway Venture Partners (Board of Directors)
RP
Roy Perlis, MD
Director, Center of Experimental Drugs & Diagnostics, Massachusetts General Hospital; Professor of Psychiatry, Harvard Medical School (Scientific Advisory Board)
MT
Madhukar Trivedi, MD
Chief of the Division of Mood Disorders and Director of the Center for Depression Research and Clinical Care, UT Southwestern Medical Center; Professor of Psychiatry, UT Southwestern Medical School (Scientific Advisory Board)
CC
Carlos Cruchaga, PhD
Professor of Psychiatry and Neurology, Washington University School of Medicine (Scientific Advisory Board)